Concepedia

Noah Post

NP

Statistics

Publications

14

Citations

767

H-Index

13

Active since

2008

Affiliations

Ionis Pharmaceuticals (United States)(Current)

Pfizer (United States)

GlaxoSmithKline (United States)

Framingham State University

Takeda (United States)

Noah Post is an author at Ionis Pharmaceuticals (United States) specializing in antisense rnas, pharmacology, and pharmacy.

Publications per year

2008–2024

14

Publications

14

Txnip balances metabolic and growth signaling via PTEN disulfide reduction

Simon T. Hui, Allen M. Andres, Amber K. Miller et al. · Proceedings of the National Academy of Sciences · 2008 · 217 citations · Full text

, , +17

Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice

Rosie Z. Yu, Mark Graham, Noah Post et al. · Molecular Therapy — Nucleic Acids · 2016 · 92 citations · Full text

, , +12

Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models

Youngsoo Kim, Minji Jo, Joanna Schmidt et al. · Molecular Therapy · 2019 · 76 citations · Full text

, , +17

Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys

Rosie Z. Yu, Rudy Gunawan, Noah Post et al. · Nucleic Acid Therapeutics · 2016 · 73 citations

, , +12

Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys

Colby S. Shemesh, Rosie Z. Yu, Hans Gaus et al. · Molecular Therapy — Nucleic Acids · 2016 · 57 citations · Full text

, , +15

1–5 of 14